Literature DB >> 34091550

Vaccine allergy: evidence to consider for COVID-19 vaccines.

Lennart Nilsson1, Ágnes Csuth1, Jann Storsaeter2, Lene H Garvey3,4, Maria C Jenmalm5.   

Abstract

PURPOSE OF REVIEW: Whereas the COVID-19 pandemic has changed our lives worldwide, we hope that vaccination can combat the disease. We propose how to evaluate suspected severe allergic reactions to the vaccines so that as many as possible may be safely vaccinated. RECENT
FINDINGS: Rare cases of severe allergic reactions after COVID-19 vaccination have been observed, seemingly at a higher frequency than for other vaccines. Few excipients are likely to have caused these reactions. IgE-mediated reactions to polyethylene glycol (PEG) and its derivatives are the most suspected, albeit hitherto unproven, causes. We suggest to make a diagnosis based on skin tests with PEG and PEG derivatives and that these be considered in relation to the decisions required before the first and the second vaccine dose. A vaccine without these excipients is available, but published data about its side effects are limited.
SUMMARY: The underlying immunological mechanisms of the rare severe allergic reactions to the COVID-19 vaccines are poorly understood and need to be clarified. Identifying those who have an undiagnosed allergy to PEG and PEG derivatives is crucial before vaccination, and these substances are found in laxatives, cosmetics and in 30% of all our medications today.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Year:  2021        PMID: 34091550     DOI: 10.1097/ACI.0000000000000762

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  9 in total

1.  Reader comments.

Authors:  Nicholas G Kounis; Virginia Mplani; Ioanna Koniari; Panagiotis Plotas
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-04-29

2.  Protocol of safe vaccination against COVID-19 in patients with high risk of allergic reactions.

Authors:  Jan Romantowski; Jerzy Kruszewski; Oskar Solarski; Andrzej Bant; Andrzej Chciałowski; Ilona Pietrzyk; Patrycja Sańpruch; Aleksandra Górska; Marta Chełmińska; Agata Knurowska; Marika Gawinowska; Ewa Jassem; Marek Niedoszytko
Journal:  Clin Transl Allergy       Date:  2022-05-17       Impact factor: 5.657

3.  Allergy to polyethylene glycol and polysorbates in a patient cohort: Diagnostic work-up and decision points for vaccination during the COVID-19 pandemic.

Authors:  Charlotte G Mortz; Henrik F Kjaer; Trine H Rasmussen; Helene M Rasmussen; Lene Heise Garvey; Carsten Bindslev-Jensen
Journal:  Clin Transl Allergy       Date:  2022-01-08       Impact factor: 5.871

4.  Psoriatic flare following Oxford-AstraZeneca ChAdOx1 COVID-19 and influenza vaccines.

Authors:  Natalie Teh; Liang Joo Leow
Journal:  Health Promot Perspect       Date:  2021-12-19

5.  The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine.

Authors:  Marina Labella; Jose Antonio Céspedes; Inmaculada Doña; Mohamed H Shamji; Ioana Agache; Cristobalina Mayorga; Maria José Torres
Journal:  Allergy       Date:  2021-10-31       Impact factor: 14.710

6.  COVID-19 vaccines and anaphylaxis-evaluation with skin prick testing, basophil activation test and Immunoglobulin E.

Authors:  Àgnes Csuth; Anna Nopp; Jann Storsaeter; Lennart Nilsson; Maria C Jenmalm
Journal:  Clin Exp Allergy       Date:  2022-04-28       Impact factor: 5.401

7.  Anaphylaxis to SARS-CoV-2 Vaccines in the Setting of a Nationwide Passive Epidemiological Surveillance Program.

Authors:  Carla Toledo-Salinas; Selma Cecilia Scheffler-Mendoza; Lina Maria Castano-Jaramillo; José Antonio Ortega-Martell; Blanca Estela Del Rio-Navarro; Ana María Santibáñez-Copado; José Luis Díaz-Ortega; Raúl Baptista-Rosas; Paulina Sánchez-Novoa; Miguel García-Grimshaw; Sergio Iván Valdés-Ferrer; Gustavo Reyes-Terán; David Alejandro Mendoza-Hernández
Journal:  J Clin Immunol       Date:  2022-08-17       Impact factor: 8.542

8.  Monitoring Anti-PEG Antibodies Level upon Repeated Lipid Nanoparticle-Based COVID-19 Vaccine Administration.

Authors:  Giuditta Guerrini; Sabrina Gioria; Aisha V Sauer; Simone Lucchesi; Francesca Montagnani; Gabiria Pastore; Annalisa Ciabattini; Donata Medaglini; Luigi Calzolai
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

9.  Evaluation of the Autoimmunity and Preexisting Risky Conditions for Hypersensitivity Reactions to COVID-19 Vaccines.

Authors:  Can Tuzer; Kadriye Terzioglu
Journal:  Int Arch Allergy Immunol       Date:  2022-02-03       Impact factor: 3.767

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.